Business in the Burbs

EpiCept stock jumps after drug review

July

EpiCept Corp. of Eastview saw its stock price jump after it said it obtained a key European approval for Ceplene, its treatment for a common form of adult leukemia. The Committee for Medicinal Products for Human Use issued a positive opinion regarding the marketing of Ceplene. The drug is administered in conjunction with low-dose Interleuken 2. Stock of EpiCept closed today at 81 cents, up 51 cents.

This entry was posted on Friday, July 25th, 2008 at 4:29 pm by Jerry Gleeson.
You can follow any responses to this entry through the RSS 2.0 feed.
Print | Email

It is a condition of your use of the comment features associated with the blogs that you do not: Use the site to post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including without limitation any transmissions constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or international law. You alone are responsible for the material you post or send. Refer to the Terms of Service.